Cephalon drops collaboration with Alkermes for Vivitrol
Alkermes said its partnership with Cephalon on Vivitrol, an injectable treatment for alcoholism, was discontinued. The decision, which is a result of Cephalon's portfolio evaluation, comes months after U.S. health authorities said they got 196 reported cases of complications from people who took Vivitrol.
Reuters | 12/01
This story published in FMI Pharmacy dailyLead on 12/02/2008
More from SmartBrief:
FDA approves Covidien's generic Actiq
Monday, November 2, 2009
Teva introduces generic copy of chemo treatment Eloxatin
Wednesday, August 12, 2009
Wyeth to return Relistor rights to Progenics
Thursday, October 15, 2009
Get stories like these delivered daily for FREE:
|
FMI Pharmacy dailyLead
Designed specifically for pharmacy professionals, FMI Pharmacy dailyLead is a FREE, daily e-mail newsletter. It provides the latest news in the pharmacy arena. Learn more |
|